<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03787498</url>
  </required_header>
  <id_info>
    <org_study_id>PLX124-02</org_study_id>
    <nct_id>NCT03787498</nct_id>
  </id_info>
  <brief_title>A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome</brief_title>
  <official_title>A Phase 1b Dose-escalation Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Plexxikon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Plexxikon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics
      and preliminary efficacy of the investigational drug PLX2853 in subjects with Relapsed or
      Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>First dose of study drug through at least 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) of PLX2853</measure>
    <time_frame>From first dose of PLX2853 up to 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax) of PLX2853</measure>
    <time_frame>From first dose of PLX2853 up to 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to peak concentration (Tmax) of PLX2853</measure>
    <time_frame>From first dose of PLX2853 up to 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half life (t1/2) of PLX2853</measure>
    <time_frame>From first dose of PLX2853 up to 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination rate constant (Kel)</measure>
    <time_frame>From first dose of PLX2853 up to 30 days after end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience dose limiting toxicity as defined in the protocol</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Dose escalation will be guided by a modified continuous reassessment method (mCRM) using a Bayesian logistic regression model that follows the escalation with overdose control (EWOC) principle. In this method, a decision to escalate to the next dose level is based on a review of all subjects who have completed the DLT observation period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall complete remission (OCR) rate</measure>
    <time_frame>From the first dose of study drug until the date of documented best response to treatment, assessed up to 18 months</time_frame>
    <description>AML — Complete Remission (CR) + CR with incomplete hematological recovery (CRi); MDS — CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>From the first dose of study drug until the date of documented response to treatment, assessed up to 18 months</time_frame>
    <description>AML — Complete Remission (CR) + CR with incomplete hematologic recovery (CRi) + Partial Remission (PR); MDS — CR + PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>DOR defined as the time from the initial objective response to disease progression or death, whichever occurs first, assessed up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>EFS time is defined as the time from the first dose of PLX2853 to treatment failure, relapse after initial response or death from any cause, assessed up to 18 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>PFS time is defined as the time from the first dose of PLX2853 to disease progression or death, whichever occurs first, assessed up to 18 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the first dose of study drug until the date of death from any cause, assessed up to 18 months.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Relapsed Acute Myeloid Leukemia (AML)</condition>
  <condition>Refractory Acute Myeloid Leukemia (AML)</condition>
  <condition>High-risk Myelodysplastic Syndrome (MDS)</condition>
  <arm_group>
    <arm_group_label>PLX2853</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 30 subjects will be enrolled as part of dose escalation to identify the MTD/RP2D of PLX2853. Up to 6 additional subjects may be enrolled at the MTD/RP2D to further characterize the PK and PDy of PLX2853.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLX2853</intervention_name>
    <description>Tablets</description>
    <arm_group_label>PLX2853</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed diagnosis of one of the following myeloid malignancies, based on the 2016
             revision of the World Health Organization classification:

             A. Relapsed or refractory AML.

             I. Subjects must have received no more than 3 prior induction therapies and have no
             standard therapeutic option that is expected to result in a clinical benefit.

             B. Relapsed or refractory MDS.

             I. Subjects must have high-risk disease (intermediate or greater disease according to
             the revised International Prognostic Scoring System [IPSS-R]).

             II. Subjects must have received no more than 3 prior therapies, 1 of which must have
             included a hypomethylating agent such as azacytidine or decitabine.

             III. Subjects must have no standard therapeutic option that is expected to result in a
             clinical benefit.

          2. Age ≥18 years.

          3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.

          4. Life expectancy of ≥3 months in the judgment of the investigator.

          5. Adequate renal, hepatic, and coagulation parameters:

             A. Measured or calculated (Cockcroft-Gault formula) creatinine clearance (CrCl) ≥60
             mL/min.

             B. Total bilirubin ≤1.5 × ULN unless due to Gilbert's syndrome.

             C. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN.

             D. Prothrombin time or international normalized ratio ≤1.5 × ULN.

             E. Activated partial thromboplastin time ≤1.5 × ULN.

          6. Women of child-bearing potential must have a negative pregnancy test at Screening and
             must agree to use an effective form of contraception from the time of the negative
             pregnancy test to 90 days after the last dose of study drug. Effective forms of
             contraception include abstinence, hormonal contraception in conjunction with a barrier
             method, or a double barrier method. Women of non-child-bearing potential may be
             included if they are either surgically sterile or have been postmenopausal for ≥ 1
             year.

          7. Fertile men must agree to use an effective method of birth control during the study
             and for 90 days after the last dose of study drug.

          8. Resolution (to ≤Grade 1 or baseline) of all significant toxicity associated with prior
             cancer therapy prior to study drug initiation. (Grade 2 alopecia or residual Grade 2
             peripheral neuropathy is allowed.)

          9. Willingness and ability to provide written informed consent prior to any study-related
             procedures and to comply with all study requirements.

        Exclusion Criteria:

          1. Prior treatment with a bromodomain inhibitor.

          2. Any one of the following therapies:

             A. Stem cell transplantation within 90 days of study drug initiation;

             B. Active immunosuppressive therapy for graft-versus-host disease (GVHD);

             C. GVHD prophylaxis within 2 weeks of study drug initiation.

          3. Known uncontrolled fungal, bacterial, and/or viral infection ≥Grade 2.

          4. Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia.

          5. Active symptomatic central nervous system involvement of AML. (Individuals who have
             had leptomeningeal disease that was effectively treated are eligible.)

          6. A diagnosis of acute promyelocytic leukemia or chronic myeloid leukemia in blast
             crisis.

          7. Known or suspected allergy to the study drug or any agent given in association with
             this trial.

          8. Women who are either pregnant or breast feeding.

          9. Clinically significant cardiac disease.

         10. Inability to take oral medication or significant nausea and vomiting, malabsorption,
             or significant small bowel resection that, in the opinion of the Investigator, would
             preclude adequate absorption.

         11. Individuals who are known to be infected with HIV, hepatitis B virus (HBV), or
             hepatitis C virus (HCV) or are known carriers of HBV or HCV. Individuals who are
             positive for HCV antibody must be negative for HCV RNA by polymerase chain reaction
             (PCR) to be eligible. Individuals with occult or prior HBV infection (defined as being
             seropositive for total hepatitis B core antibody and seronegative for hepatitis B
             surface antigen) may be included if HBV DNA is undetectable. These individuals must be
             willing to undergo additional testing per local standard of care.

         12. Active second malignancy with the exception of any of the following:

               -  Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or
                  in situ cervical cancer;

               -  Adequately treated Stage I cancer from which the subject is currently in
                  remission and has been in remission for ≥2 years;

               -  Low-risk prostate cancer with Gleason score &lt;7 and prostate-specific antigen &lt;10
                  ng/mL;

               -  Any other cancer from which the patient has been disease-free for ≥3 years.

         13. Major surgery or significant injury within the 14-day period prior to study drug
             initiation.

         14. Anti-cancer therapy in the period immediately preceding study drug initiation.

         15. Any other medical, psychological, familial, sociologic, or geographic condition that,
             in the judgement of the investigator, would potentially hamper compliance with the
             study protocol or interfere with the study endpoints or the subject's ability to
             participate in the study.

         16. Participation in any other therapeutic clinical study. (Participation in observational
             or registry trials is allowed.)

         17. Individuals who are on active anticoagulation therapy (e.g., warfarin, factor Xa
             inhibitors, thrombin inhibitors, heparin).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paul Watkins</last_name>
    <phone>510-647-4151</phone>
    <email>PWatkins@plexxikon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Brown</last_name>
      <phone>404-780-7965</phone>
      <email>stacey.brown@northside.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer At Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>27287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Dezern, MD</last_name>
      <phone>410-502-7208</phone>
      <email>adezern1@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NewYork-Presbyterian / Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Mendez</last_name>
      <phone>212-746-2141</phone>
      <email>vib9049@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>614-293-3316</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>503-494-1080</phone>
      <email>Trials@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naveen Pemmaraju</last_name>
      <phone>713-792-4956</phone>
      <email>npemmaraju@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 23, 2018</study_first_submitted>
  <study_first_submitted_qc>December 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2018</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PLX2853</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>Hematologic Malignancy</keyword>
  <keyword>Blood Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

